UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2012
NUTRACEUTICAL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware |
|
000-23731 |
|
87-0515089 |
(State of incorporation) |
|
(Commission |
|
(IRS Employer |
|
|
File Number) |
|
Identification No.) |
1400 Kearns Boulevard, 2nd Floor |
|
|
Park City, Utah |
|
84060 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (435) 655-6106
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On April 26, 2012, Nutraceutical International Corporation (Nutraceutical) reported results for the fiscal 2012 second quarter ended March 31, 2012. The press release reporting the results is attached to this Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibits.
99.1 Press release issued by Nutraceutical dated April 26, 2012.
This Form 8-K and the attached Exhibit are furnished to comply with Item 2.02 and Item 9.01 of Form 8-K. Neither this Form 8-K nor the attached Exhibit are to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall this Form 8-K nor the attached Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933 (except as shall be expressly set forth by specific reference in such filing).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NUTRACEUTICAL INTERNATIONAL CORPORATION | |
|
(Registrant) | |
|
|
|
|
By: |
/s/ Cory J. McQueen |
Date: April 26, 2012 |
|
Cory J. McQueen |
|
|
Vice President and Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
Exhibit 99.1
FOR: |
|
NUTRACEUTICAL INTERNATIONAL CORPORATION |
|
|
|
CONTACT: |
|
Cory McQueen |
|
|
Vice President and |
|
|
Chief Financial Officer |
|
|
(435) 655-6106 |
NUTRACEUTICAL REPORTS FISCAL 2012 Q2 RESULTS AND EXPANDS SHARE REPURCHASE PROGRAM
PARK CITY, Utah, Apr 26/PRNewswire/Nutraceutical International Corporation (NASDAQ: NUTR) today reported results for the fiscal 2012 second quarter ended March 31, 2012. Net sales for the fiscal 2012 second quarter were $53.9 million compared to $49.5 million for the same quarter of fiscal 2011. For the second quarter of fiscal 2012, net income was $4.8 million, or $0.49 diluted earnings per share, compared to net income of $4.6 million, or $0.44 diluted earnings per share, for the same quarter of fiscal 2011.
Net sales for the six months ended March 31, 2012 were $100.5 million compared to $94.8 million for the same period in fiscal 2011. For the six months ended March 31, 2012, net income was $8.2 million, or $0.82 per diluted share, compared to net income of $8.5 million, or $0.81 per diluted share, for the same period of fiscal 2011.
Operating cash flow for the six months ended March 31, 2012 was $17.3 million compared to $15.7 million for the same period of fiscal 2011. This operating cash flow was primarily used to invest $6.5 million in acquisitions of natural product businesses, $4.7 million in purchases of property and equipment and $3.8 million in repurchases of common stock.
Bill Gay, chairman and chief executive officer, commented, Our Fiscal 2012 second quarter net sales growth of 8.7% was generated domestically, internationally and from acquisitions made over the last year. Net income primarily increased as a result of the quarterly net sales growth and we expect net income to remain strong in the near future, although its continued expansion will be limited by manufacturing overhead costs associated with the integration of our new manufacturing facilities, freight increases and payroll. Over the coming year, we will continue to focus on improving the efficiency and utilization of all of our manufacturing facilities. Cash flow and EBITDA are strong and investments will continue to be made in manufacturing equipment and technology.
Mr. Gay stated, Recently, the Health and Natural Food Store market seems to have been stronger than the overall economy and we hope this strength continues into the future. We have ongoing concerns about the increasing complexity and expansion of state, federal and international laws and regulations. The identification and acquisition of unique branded product companies remains a key focus and the success of this effort is fundamental to our long-term growth and is basic to our business strategy. We appreciate the continuing support of our employees and shareholders in building our business.
Mr. Gay continued, I am also pleased to announce that on April 23, 2012, our Board of Directors agreed to add an additional one million shares to our previously approved share purchase program which means the Company is now authorized to buy up to approximately 1.2 million total additional shares of our outstanding common stock. Under this approved share purchase program, the Company may purchase common stock from time to time on the open market and in individually negotiated transactions. The amount and timing of any purchases will be dependent upon a number of factors, including the price and availability of the Companys shares and general market conditions. The Company currently has approximately 9.9 million shares of its common stock outstanding. From October 1, 2003 through March 31, 2012, the Company purchased 2.6 million shares of its common stock at an average price of $13.21 per share for an aggregate purchase price of $34.4 million.
ABOUT NUTRACEUTICAL
We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.
We manufacture and sell nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Natures Life®, LifeTime®, Natural Balance®,
bioAllers®, Herbs for Kids, NaturalCare®, Health from the Sun®, Life-flo®, Organix South®, Pioneer® and Monarch Nutraceuticals.
We own neighborhood natural food markets, which operate under the trade names The Real Food Company, Thoms Natural Foods and Cornucopia Community Market. We also own health food stores, which operate under the trade names Fresh Vitamins, Granolas, Natures Discount and Warehouse Vitamins.
We manufacture and/or distribute one of the broadest branded product lines in the industry with over 6,000 SKUs, including approximately 700 SKUs sold internationally. We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as believe, expects, plan, intend, may, will, should, can, or anticipates, or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control. Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SECs website (www.sec.gov).
© 2012 Nutraceutical Corporation. All rights reserved.
# # #
NUTRACEUTICAL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited; dollars in thousands)
|
|
March 31, |
|
September 30, |
| ||
|
|
2012 |
|
2011 |
| ||
Assets |
|
|
|
|
| ||
Current assets, net |
|
$ |
64,821 |
|
$ |
62,069 |
|
Property, plant and equipment, net |
|
73,705 |
|
72,094 |
| ||
Goodwill |
|
12,110 |
|
8,853 |
| ||
Other non-current assets, net |
|
27,364 |
|
28,649 |
| ||
|
|
$ |
178,000 |
|
$ |
171,665 |
|
|
|
|
|
|
| ||
Liabilities and Stockholders Equity |
|
|
|
|
| ||
Current liabilities |
|
$ |
20,908 |
|
$ |
19,737 |
|
Long-term liabilities |
|
32,355 |
|
32,253 |
| ||
Stockholders equity |
|
124,737 |
|
119,675 |
| ||
|
|
$ |
178,000 |
|
$ |
171,665 |
|
NUTRACEUTICAL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited; dollars in thousands, except per share data)
|
|
Three months ended March 31, |
|
Six months ended March 31, |
| ||||||||
|
|
2012 |
|
2011 |
|
2012 |
|
2011 |
| ||||
Net sales |
|
$ |
53,871 |
|
$ |
49,549 |
|
$ |
100,499 |
|
$ |
94,792 |
|
Cost of sales |
|
26,883 |
|
24,135 |
|
50,253 |
|
45,916 |
| ||||
Gross profit |
|
26,988 |
|
25,414 |
|
50,246 |
|
48,876 |
| ||||
Operating expenses |
|
|
|
|
|
|
|
|
| ||||
Selling, general and administrative |
|
18,656 |
|
17,512 |
|
35,796 |
|
34,247 |
| ||||
Amortization of intangible assets |
|
471 |
|
404 |
|
945 |
|
794 |
| ||||
Income from operations |
|
7,861 |
|
7,498 |
|
13,505 |
|
13,835 |
| ||||
Interest and other expense, net |
|
377 |
|
338 |
|
736 |
|
509 |
| ||||
Income before provision for income taxes |
|
7,484 |
|
7,160 |
|
12,769 |
|
13,326 |
| ||||
Provision for income taxes |
|
2,654 |
|
2,608 |
|
4,528 |
|
4,827 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
4,830 |
|
$ |
4,552 |
|
$ |
8,241 |
|
$ |
8,499 |
|
|
|
|
|
|
|
|
|
|
| ||||
Net income per common share |
|
|
|
|
|
|
|
|
| ||||
Basic |
|
$ |
0.49 |
|
$ |
0.44 |
|
$ |
0.82 |
|
$ |
0.82 |
|
Diluted |
|
0.49 |
|
0.44 |
|
0.82 |
|
0.81 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
| ||||
Basic |
|
9,938,593 |
|
10,371,037 |
|
9,992,200 |
|
10,374,816 |
| ||||
Diluted |
|
9,947,012 |
|
10,425,564 |
|
10,003,851 |
|
10,443,867 |
|
NUTRACEUTICAL INTERNATIONAL CORPORATION
EBITDA SCHEDULE
(unaudited; dollars in thousands)
|
|
Three months ended March 31, |
|
Six months ended March 31, |
| ||||||||
|
|
2012 |
|
2011 |
|
2012 |
|
2011 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
4,830 |
|
$ |
4,552 |
|
$ |
8,241 |
|
$ |
8,499 |
|
Provision for income taxes |
|
2,654 |
|
2,608 |
|
4,528 |
|
4,827 |
| ||||
Interest and other expense, net (1) |
|
377 |
|
338 |
|
736 |
|
509 |
| ||||
Depreciation and amortization |
|
2,123 |
|
2,033 |
|
4,208 |
|
3,975 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
EBITDA |
|
$ |
9,984 |
|
$ |
9,531 |
|
$ |
17,713 |
|
$ |
17,810 |
|
(1) Includes amortization of deferred financing fees.
Non-GAAP Financial Measures
EBITDA (a non-GAAP measure) is defined in our debt covenants and performance measures as earnings before net interest and other expense, taxes, depreciation and amortization. We believe that EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance. EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation. Furthermore, EBITDA is not intended to be an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.